Appointed
Steven Nathan
Class I director
GOSS ·
Gossamer Bio, Inc.
Steven Nathan, M.D. to serve as a Class I director effective March 11, 2024
Ready 8-Ks
26
Latest filing
June 4, 2026, 7:28 PM ET
Top materiality
0.90
Event mix
other_material ×8 · earnings ×7 · debt ×3
Sentiment
9 pos · 4 neg · 13 neu
Latest earnings
reported 2025-Q3
Executive change
recent →
Recent 8-K filings for GOSS
Highest-materiality recent filing
Gossamer Bio reports 2025 net loss $170.4M; seralutinib Phase 3 narrowly missed primary endpoint
- PROSERA Phase 3 in PAH showed placebo-adjusted 6MWD +13.3 meters but missed prespecified statistical alpha of 0.025 (p=0.0320).
- Enrollment in Phase 3 SERANATA (PH-ILD) paused; Company evaluating implications and plans FDA Type C meeting in June 2026.
-
Gossamer Bio exchanges 90.5% of 5% notes for new 7.5% notes, stock, and warrants
$181M of 5% Convertible Senior Notes due 2027 tendered and cancelled (90.5% of outstanding).
-
Gossamer Bio shareholders re-elect directors, ratify EY, approve say-on-pay
Faheem Hasnain re-elected as Class II director with 92.3M for, 26.7M withheld, 45.5M broker non-votes.
-
Gossamer Bio extends early tender deadline for exchange offer; $181M of notes tendered
Early tender deadline extended to 5:00 p.m. ET on June 2, 2026; early settlement expected June 4, 2026.
-
Gossamer Bio launches exchange offer for 5.00% notes; holders of 75.2% support
Exchange Offer: up to $72M new 7.50% Convertible Secured Notes due 2030, plus up to 317.6M common shares and 150M Purchase Warrants.
-
Gossamer Bio receives Nasdaq bid price deficiency notice; 180 days to cure
Nasdaq notified Gossamer on April 8, 2026 that stock bid price <$1.00 for 30 consecutive business days (Feb 24 – Apr 7, 2026).
-
Gossamer Bio reports 2025 net loss $170.4M; seralutinib Phase 3 narrowly missed primary endpoint
PROSERA Phase 3 in PAH showed placebo-adjusted 6MWD +13.3 meters but missed prespecified statistical alpha of 0.025 (p=0.0320).
-
Primary 6MWD endpoint missed: +13.3m placebo-adjusted (p=0.0320 vs prespecified α=0.025).
-
Gossamer Bio Q3 net loss $48.2M; PROSERA topline due Feb 2026
Net loss of $48.2M ($0.21 per share) vs $30.8M loss a year ago; revenue from Chiesi collab $13.3M.
-
Gossamer Bio issues 2.5M shares for option to acquire Respira Therapeutics
Issued 2,500,000 shares to Prana Bio on Sept 24, 2025 as consideration for option to acquire Respira via merger.
-
Gossamer Bio Q2 net loss $38.3M; PROSERA Phase 3 topline due Feb 2026
Net loss $38.3M ($0.17 per share) vs net income $49.2M in Q2 2024, driven by $88.8M one-time license revenue in prior year.
-
Stockholders re-elect three Class I directors, approve amended incentive plan
Class I directors re-elected: Thomas Daniel, Sandra Milligan, Steven Nathan.
-
Gossamer Bio completes enrollment in Phase 3 PROSERA study for seralutinib in PAH (n=390)
Global registrational Phase 3 PROSERA study fully enrolled; topline results expected February 2026.
-
Gossamer Bio closes new patient screening in PAH Phase 3 PROSERA study; Q1 net loss $36.6M
Enrollment of 343 patients completed; to exceed 350 by early June; topline results expected Feb 2026.
-
Gossamer Bio Q4 2024 net loss $33M; PROSERA Phase 3 topline due Q4 2025
Cash, equivalents and marketable securities $294.5M at year-end; runway into H1 2027.
-
Gossamer Bio regains Nasdaq minimum bid price compliance; deficiency closed.
Received Nasdaq notice on Feb 19, 2025 confirming regained compliance with minimum bid price rule.
-
Gossamer Bio Q3 net loss $30.8M; cash $327M, runway into H1 2027
Net loss of $30.8M ($0.14/share) vs $40.0M ($0.21/share) in Q3 2023; revenue from Chiesi collaboration was $9.5M.
-
Gossamer Bio receives Nasdaq bid-price deficiency notice; deadline March 2025
Nasdaq notified Gossamer Bio that its stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Sept 10, 2024.
-
Gossamer Bio Q2 2024 net income $49.2M; cash $354.5M; Chiesi collaboration on track
Net income $49.2M ($0.22 basic EPS) vs net loss $42.5M in Q2 2023.
-
Gossamer Bio regains Nasdaq minimum bid price compliance; listing matter closed
Received Nasdaq letter on July 18, 2024 confirming regained compliance with minimum bid price rule.
-
Gossamer Bio reports annual meeting results; all proposals approved
Skye Drynan and John Quisel re-elected as Class II directors for three-year terms.
-
Gossamer Bio receives Nasdaq minimum bid deficiency; cure period to Nov 18, 2024
Nasdaq notice on May 22, 2024; stock below $1.00 for 30 consecutive business days through May 21.
-
Gossamer Bio reports Q1 net loss $41.9M; announces Chiesi collaboration for seralutinib
Chiesi collaboration provides $160M upfront; Gossamer and Chiesi split global development costs, profits in US.
-
Gossamer Bio enters global collaboration with Chiesi for seralutinib; receives $160M upfront
Receives $160M development reimbursement; eligible for up to $146M regulatory and $180M sales milestones.
-
Gossamer Bio appoints Dr. Nathan (PH-ILD expert) and biotech analyst Drynan to board
Dr. Steven Nathan appointed as Class I director, effective March 11, 2024; brings pulmonary and PH-ILD expertise.
-
Gossamer Bio Q4/FY23 results: first PAH patient dosed in Phase 3 PROSERA, cash $296M into H1 2026
First PAH patient dosed in registrational Phase 3 PROSERA study; topline results expected Q4 2025.
-
Gossamer Bio regains Nasdaq minimum bid price compliance; deficiency closed
Received Nasdaq letter on March 4, 2024 confirming compliance with minimum bid price rule.
Executive changes
Appointed
Skye Drynan
Class III director
GOSS ·
Gossamer Bio, Inc.
appointed Skye Drynan to serve as a Class III director effective March 11, 2024
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.68 · Most common event other_material